Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Techno Medica Co., Ltd. ( (JP:6678) ) has shared an update.
Techno Medica reported a strong recovery in its non-consolidated results for the fiscal year ended March 31, 2026, with net sales rising 13.4% to ¥11.24 billion and operating profit climbing 28.3% to ¥1.67 billion. Ordinary profit increased 31.8% and earnings per share improved to ¥155.28, while return on equity and margins also strengthened, underscoring improved profitability after the previous year’s declines.
The company maintained a solid financial position, with total assets roughly flat at ¥17.97 billion and an equity ratio of 80.2%, and it generated positive operating cash flow of ¥1.1 billion despite higher dividend payouts and financing outflows. Reflecting its stronger earnings, Techno Medica more than doubled its annual dividend to ¥129 per share for fiscal 2026 and plans a still-elevated ¥93 per share for the current year, signaling a continued emphasis on shareholder returns even as cash and cash equivalents edged slightly lower.
More about Techno Medica Co., Ltd.
Techno Medica Co., Ltd. is a Japan-based medical technology company listed on the Tokyo Stock Exchange. It develops and sells medical devices and related systems, focusing on solutions for clinical settings that support healthcare providers and institutions in the domestic market.
Average Trading Volume: 9,000
Technical Sentiment Signal: Buy
Current Market Cap: Yen19.36B
Learn more about 6678 stock on TipRanks’ Stock Analysis page.